Doing a proper Net Present Value discount calculation right now would challenge Carl Gauss with so many variables as to likelihood of approval and date of same for the various approaches and timelines for spread to jurisdictions outside of the USA.
Have always thought CSL will be the underling to MSB in the long term if left alone.
I see Newcastle Uni is involved in stem cell research in regard to cancer. Not all stem cells are good for those interested. Nothing to do with MSB.
MESO Nasdaq update, page-5005
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.010(0.64%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.52 | $5.031M | 3.197M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 5196 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 25614 | 9 |
View Market Depth
| Last trade - 14.45pm 18/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |